LOGIN  |  REGISTER
Assertio
C4 Therapeutics

Omnicell to Host Innovation Update and Q&A Session at Upcoming ASHP Midyear Industry Trade Show

December 01, 2025 | Last Trade: US$38.46 2.34 6.48

FORT WORTH, Texas / Dec 01, 2025 / Business Wire / Omnicell, Inc. (Nasdaq: OMCL), a leader in transforming the pharmacy and nursing care delivery model, will host an Innovation Update and Investor Q&A Session during the upcoming ASHP Midyear Clinical Meeting & Exhibition in Las Vegas.

Innovation Update – in person only at Booth #1241
Monday, December 8, 2025
3:00 pm PT

Q&A Session – in person and webcast
Monday, December 8, 2025
4:00 pm PT

Omnicell Speakers:

Randall Lipps, Chairman, President, Chief Executive Officer, and Founder
Nnamdi Njoku, Executive Vice President, Chief Operating Officer
Baird Radford, Executive Vice President, Chief Financial Officer

A live and archived webcast of the Q&A session will be available through the Omnicell website at: https://ir.omnicell.com/events-and-presentations/

About Omnicell

Since 1992, Omnicell has been committed to transforming pharmacy and nursing care through outcomes-centric solutions designed to deliver clinical and business outcomes across all settings of care. Through a comprehensive portfolio of robotics and smart devices, intelligent software workflows, and data and analytics, all optimized by expert services, Omnicell solutions are helping healthcare facilities worldwide to uncover cost savings, improve labor efficiency, establish new revenue streams, enhance supply chain control, support compliance, and move closer to the industry-defined vision of the Autonomous Pharmacy. To learn more, visit omnicell.com.

OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries.

 

Assertio

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page